How Continuous Glucose Monitors May Track Teplizumab's Early Effects

Teplizumab delays the onset of Type 1 diabetes in people with early signs of the autoimmune disease. But doctors currently rely on A1C tests and other markers to assess whether the treatment is working—tools that can be slow to show change. Researchers wondered whether continuous glucose monitors, which track blood sugar patterns minute by minute, might reveal teplizumab's effects sooner and more clearly.

Researchers followed five children with stage 2 Type 1 diabetes (early autoimmune disease before diabetes diagnosis) who received teplizumab. They monitored the children for 8 to 19 months using CGM data, looking at two key patterns: how much blood sugar bounced around (glycemic variability) and how much time they spent above 140 mg/dL.

Four of the five children showed stabilization or improvement in these glucose patterns within 3 to 6 months of treatment. One child, however, showed worsening glucose variability and larger blood sugar swings over time—and progressed to stage 3 diabetes within 4 months. Notably, these early differences in CGM patterns were not yet reflected in standard A1C measurements.

The findings suggest that CGM might act as an early warning system after teplizumab treatment. It could help doctors understand which children are responding positively and, potentially, identify those at risk of progressing despite therapy—all months before conventional tests catch up.

However, the researchers emphasize that these findings are preliminary. They are based on just five children and should be viewed as a starting point for future research, not proof that this approach will work in larger groups. Larger studies are now needed to confirm whether CGM metrics can reliably predict treatment response and help guide patient monitoring going forward.

This research opens a new avenue for monitoring teplizumab and other immunomodulatory therapies in early Type 1 diabetes. If validated in bigger studies, CGM-based monitoring could become a practical tool for families and clinicians to track whether treatment is having the desired effect—and to catch early signs of disease progression sooner than today's standard approach allows.

Source: Diabetes technology & therapeutics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.